INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IUI1 - US46120E6023 - Common Stock
453.9 EUR
-10.45 (-2.25%)
Overall IUI1 gets a fundamental rating of 6 out of 10. We evaluated IUI1 against 67 industry peers in the Health Care Equipment & Supplies industry. IUI1 has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. IUI1 is valued quite expensively, but it does show have an excellent growth rating. With these ratings, IUI1 could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
- In the past year IUI1 was profitable.
- In the past year IUI1 had a positive cash flow from operations.
- IUI1 had positive earnings in each of the past 5 years.
- Each year in the past 5 years IUI1 had a positive operating cash flow.
1.2 Ratios
- IUI1 has a Return On Assets of 14.19%. This is amongst the best in the industry. IUI1 outperforms 94.03% of its industry peers.
- IUI1 has a better Return On Equity (16.12%) than 83.58% of its industry peers.
- The Return On Invested Capital of IUI1 (11.69%) is better than 82.09% of its industry peers.
- IUI1 had an Average Return On Invested Capital over the past 3 years of 9.53%. This is in line with the industry average of 9.84%.
- The 3 year average ROIC (9.53%) for IUI1 is below the current ROIC(11.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROIC | 11.69% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
1.3 Margins
- IUI1's Profit Margin of 28.58% is amongst the best of the industry. IUI1 outperforms 98.51% of its industry peers.
- In the last couple of years the Profit Margin of IUI1 has declined.
- IUI1 has a Operating Margin of 29.44%. This is amongst the best in the industry. IUI1 outperforms 98.51% of its industry peers.
- In the last couple of years the Operating Margin of IUI1 has declined.
- IUI1's Gross Margin of 66.38% is fine compared to the rest of the industry. IUI1 outperforms 73.13% of its industry peers.
- In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% |
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
- The number of shares outstanding for IUI1 has been increased compared to 1 year ago.
- The number of shares outstanding for IUI1 has been increased compared to 5 years ago.
- IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.17
WACC9.99%
2.3 Liquidity
- A Current Ratio of 4.97 indicates that IUI1 has no problem at all paying its short term obligations.
- The Current ratio of IUI1 (4.97) is better than 95.52% of its industry peers.
- A Quick Ratio of 4.20 indicates that IUI1 has no problem at all paying its short term obligations.
- With an excellent Quick ratio value of 4.20, IUI1 belongs to the best of the industry, outperforming 95.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 |
3. Growth
3.1 Past
- IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.12%, which is quite impressive.
- IUI1 shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 11.48% yearly.
- Looking at the last year, IUI1 shows a very strong growth in Revenue. The Revenue has grown by 22.18%.
- IUI1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.27% yearly.
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
3.2 Future
- Based on estimates for the next years, IUI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.67% on average per year.
- Based on estimates for the next years, IUI1 will show a quite strong growth in Revenue. The Revenue will grow by 14.12% on average per year.
EPS Next Y20.12%
EPS Next 2Y16.35%
EPS Next 3Y15.9%
EPS Next 5Y15.67%
Revenue Next Year21.33%
Revenue Next 2Y18.13%
Revenue Next 3Y16.56%
Revenue Next 5Y14.12%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 61.34, the valuation of IUI1 can be described as expensive.
- Compared to the rest of the industry, the Price/Earnings ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 61.19% of the companies listed in the same industry.
- IUI1 is valuated expensively when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 53.20 indicates a quite expensive valuation of IUI1.
- 73.13% of the companies in the same industry are cheaper than IUI1, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.29, IUI1 is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.34 | ||
| Fwd PE | 53.2 |
4.2 Price Multiples
- IUI1's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. IUI1 is more expensive than 67.16% of the companies in the same industry.
- IUI1's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 82.4 | ||
| EV/EBITDA | 51.82 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
- IUI1 has an outstanding profitability rating, which may justify a higher PE ratio.
- IUI1's earnings are expected to grow with 15.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.05
PEG (5Y)5.34
EPS Next 2Y16.35%
EPS Next 3Y15.9%
5. Dividend
5.1 Amount
- No dividends for IUI1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IUI1 (1/19/2026, 7:00:00 PM)
453.9
-10.45 (-2.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-21 2025-10-21/amc
Earnings (Next)01-22 2026-01-22/amc
Inst Owners88.29%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap160.91B
Revenue(TTM)9.61B
Net Income(TTM)2.75B
Analysts77
Price Target531.45 (17.09%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)11.61%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)13.53%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)11%
EPS beat(12)11
Avg EPS beat(12)7.6%
EPS beat(16)13
Avg EPS beat(16)5.75%
Revenue beat(2)2
Avg Revenue beat(2)2%
Min Revenue beat(2)1.84%
Max Revenue beat(2)2.17%
Revenue beat(4)4
Avg Revenue beat(4)2.55%
Min Revenue beat(4)1.09%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)1.17%
Revenue beat(12)6
Avg Revenue beat(12)0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.31%
PT rev (1m)1.34%
PT rev (3m)3.73%
EPS NQ rev (1m)0.05%
EPS NQ rev (3m)3.26%
EPS NY rev (1m)0%
EPS NY rev (3m)5.8%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)1.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.34 | ||
| Fwd PE | 53.2 | ||
| P/S | 19.47 | ||
| P/FCF | 82.4 | ||
| P/OCF | 63.21 | ||
| P/B | 10.98 | ||
| P/tB | 11.21 | ||
| EV/EBITDA | 51.82 |
EPS(TTM)7.4
EY1.63%
EPS(NY)8.53
Fwd EY1.88%
FCF(TTM)5.51
FCFY1.21%
OCF(TTM)7.18
OCFY1.58%
SpS23.31
BVpS41.33
TBVpS40.49
PEG (NY)3.05
PEG (5Y)5.34
Graham Number82.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROCE | 16.61% | ||
| ROIC | 11.69% | ||
| ROICexc | 23.14% | ||
| ROICexgc | 24.12% | ||
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% | ||
| FCFM | 23.63% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
ROICexc(3y)14.41%
ROICexc(5y)14.87%
ROICexgc(3y)15.07%
ROICexgc(5y)15.72%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexgc growth 3Y-7.59%
ROICexgc growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 111.36% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.84% | ||
| Profit Quality | 82.69% | ||
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 | ||
| Altman-Z | N/A |
F-Score8
WACC9.99%
ROIC/WACC1.17
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
EPS Next Y20.12%
EPS Next 2Y16.35%
EPS Next 3Y15.9%
EPS Next 5Y15.67%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
Revenue Next Year21.33%
Revenue Next 2Y18.13%
Revenue Next 3Y16.56%
Revenue Next 5Y14.12%
EBIT growth 1Y36.82%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year45.96%
EBIT Next 3Y24.75%
EBIT Next 5Y20.85%
FCF growth 1Y80.69%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y46.32%
OCF growth 3Y4.95%
OCF growth 5Y8.61%
INTUITIVE SURGICAL INC / IUI1.DE FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to IUI1.DE.
Can you provide the valuation status for INTUITIVE SURGICAL INC?
ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
Can you provide the profitability details for INTUITIVE SURGICAL INC?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 8 / 10.
Can you provide the financial health for IUI1 stock?
The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 7 / 10.